Dare Bioscience, Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Dare Bioscience, Inc. (DARE) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$107.46 thousand for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-12.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2019-11-12
- Dare Bioscience, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2019-09-30 was -$279.88K.
- Dare Bioscience, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2019-06-30 was $306.50K, a 512.03% increase year-over-year.
- Dare Bioscience, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2019-03-31 was -$134.09K.
- Dare Bioscience, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2018-09-30 was -$49.54K, a 145.64% decline year-over-year.
- Dare Bioscience, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2017 was $753.10K.
- Dare Bioscience, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2016 was -$723.00.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|---|---|---|
| 2019-09-30 | -$279.88K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $26.62K derived: sum of 2 quarters · filed 2019-11-12 | -$107.46K 10-Q · filed 2019-11-12 | ||||
| 2019-06-30 | $306.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $172.41K 10-Q · filed 2019-08-14 | |||||
| 2019-03-31 | -$134.09K 10-Q · filed 2019-05-14 | ||||||
| 2018-09-30 | -$49.54K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $537.00 derived: sum of 2 quarters · filed 2019-11-12 | -$39.80K 10-Q · filed 2019-11-12 | $236.26K 10-Q · filed 2018-11-13 | $54.07K derived: sum of 4 quarters · filed 2019-11-12 | ||
| 2018-06-30 | $50.08K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $9.74K 10-Q · filed 2019-08-14 | $298.58K 10-Q · filed 2018-08-13 | $103.61K derived: sum of 3 quarters · filed 2019-08-14 | $212.17K derived: sum of 4 quarters · filed 2019-08-14 | ||
| 2018-03-31 | -$40.34K 10-Q · filed 2019-05-14 | -$159.05K 10-Q · filed 2018-05-14 | $53.53K derived: sum of 2 quarters · filed 2019-05-14 | $162.09K derived: sum of 3 quarters · filed 2019-05-14 | $532.10K derived: sum of 4 quarters · filed 2019-05-14 | ||
| 2017-12-31 | $93.88K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-28 | $202.43K derived: sum of 2 quarters · filed 2018-11-13 | $572.44K derived: sum of 3 quarters · filed 2018-11-13 | $753.10K 10-K · filed 2018-03-28 | |||
| 2017-09-30 | $108.56K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $478.56K derived: sum of 2 quarters · filed 2018-11-13 | $659.22K 10-Q · filed 2018-11-13 | $671.90K derived: sum of 4 quarters · filed 2018-11-13 | |||
| 2017-06-30 | $370.01K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-13 | $550.67K 10-Q · filed 2018-08-13 | $563.34K derived: sum of 3 quarters · filed 2018-08-13 | ||||
| 2017-03-31 | $180.66K 10-Q · filed 2018-05-14 | $193.34K derived: sum of 2 quarters · filed 2018-05-14 | |||||
| 2016-12-31 | $12.68K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-28 | -$723.00 10-K · filed 2018-03-28 | |||||
| 2016-09-30 | -$13.40K 10-Q · filed 2017-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |